Commentary: Targeting Chemoattractant Chemokine (C–C Motif) Ligand 2 Derived from Astrocytes is a Promising Therapeutic Approach in the Treatment of Neuromyelitis Optica Spectrum Disorders

Jingdan Zhang,Jinbo Cheng

DOI: https://doi.org/10.3389/fimmu.2023.1279782

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:GENERAL COMMENTARY article Front. Immunol., 27 September 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1279782

What problem does this paper attempt to address?

Targeting chemoattractant chemokine (C–C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders

Yupeng Wang,Jiangping Bian,Mengyuan Yao,Li Du,Yun Xu,Haoxiao Chang,Hengri Cong,Yuzhen Wei,Wangshu Xu,Huabing Wang,Xinghu Zhang,Xingchao Geng,Linlin Yin

DOI: https://doi.org/10.3389/fimmu.2023.1144532

IF: 7.3

2023-03-29

Frontiers in Immunology

Abstract:Introduction: Aquaporin-4 immunoglobulin G (AQP4-IgG)-induced astrocytes injury is a key mechanism in the pathogenesis of neuromyelitis spectrum disorder (NMOSD), and although CCL2 is involved, its specific role has not been reported. We aimed to further investigate the role and potential mechanisms of CCL2 in AQP4-IgG-induced astrocyte injury. Methods: First, we evaluated CCL2 levels in paired samples of subject patients by automated microfluidic platform, Ella®. Second, we knock down astrocyte's CCL2 gene in vitro and in vivo to define the function of CCL2 in AQP4-IgG-induced astrocyte injury. Third, astrocyte injury and brain injury in live mice were assessed by immunofluorescence staining and 7.0T MRI, respectively. Western blotting and high-content screening were conducted to clarify the activation of inflammatory signaling pathways, and changes in CCL2 mRNA and cytokine/chemokines were measured by qPCR technique and flow cytometry, respectively. Results: There were greatly higher CSF-CCL2 levels in NMOSD patients than that in other non-inflammatory neurological diseases (OND) groups. Blocking astrocyte CCL2 gene expression can efficiently mitigate AQP4-IgG-induced damage in vitro and in vivo . Interestingly, prevention of CCL2 expression could decrease other inflammatory cytokines released, including IL-6 and IL-1β. Our data suggest that CCL2 involves in the initiation and plays a pivotal role in AQP4-IgG-damaged astrocytes. Discussion: Our results indicate that CCL2 may serve as a promising candidate target for inflammatory disorder therapy, including NMOSD.

immunology
Astrocyte-Microglia Interaction Drives Evolving Neuromyelitis Optica Lesion

Tingjun Chen,Vanda A. Lennon,Yong U. Liu,Dale B. Bosco,Yujiao Li,Min-Hee Yi,Jia Zhu,Shihui Wei,Long-Jun Wu

DOI: https://doi.org/10.1172/JCI134816

IF: 19.456

2020-01-01

Journal of Clinical Investigation

Abstract:Neuromyelitis optica (NMO) is a severe inflammatory autoimmune CNS disorder triggered by binding of an IgG autoantibody to the aquaporin 4 (AQP4) water channel on astrocytes. Activation of cytolytic complement has been implicated as the major effector of tissue destruction that secondarily involves myelin. We investigated early precytolytic events in the evolving pathophysiology of NMO in mice by continuously infusing IgG (NMO patient serum-derived or AQP4-specific mouse monoclonal), without exogenous complement, into the spinal subarachnoid space. Motor impairment and sublytic NMO-compatible immunopathology were IgG dose dependent, AQP4 dependent, and, unexpectedly, microglia dependent. In vivo spinal cord imaging revealed a striking physical interaction between microglia and astrocytes that required signaling from astrocytes by the C3a fragment of their upregulated complement C3 protein. Astrocytes remained viable but lost AQP4. Previously unappreciated crosstalk between astrocytes and microglia involving early-activated CNS-intrinsic complement components and microglial C3a receptor signaling appears to be a critical driver of the precytolytic phase in the evolving NMO lesion, including initial motor impairment. Our results indicate that microglia merit consideration as a potential target for NMO therapeutic intervention.
Editorial: Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management

Yin-Xi Zhang,Wei Qiu,Hong-Zhi Guan,Long-Jun Wu,Mei-Ping Ding

DOI: https://doi.org/10.3389/fneur.2022.844155

IF: 3.4

2022-01-01

Frontiers in Neurology

Abstract:EDITORIAL article Front. Neurol., 02 March 2022Sec. Multiple Sclerosis and Neuroimmunology https://doi.org/10.3389/fneur.2022.844155
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Nicolas Collongues,Estelle Ayme-Dietrich,Laurent Monassier,Jérôme de Seze

DOI: https://doi.org/10.1007/s40265-018-1039-7

Drugs

Abstract:Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central nervous system. Although the prevalence of NMO is low, the rapid and severe impairment observed in patients has led to extensive development of research in the fields of diagnostic criteria and therapy in the past 15 years. With improved understanding of the pathophysiology of NMO and the role of aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein antibodies, numerous therapeutic approaches have been proposed and are currently undergoing evaluation. In this review, we describe the rationale for existing therapeutics and their benefit/risk ratio. We also discuss the pharmacological and clinical interest of future approaches targeting, among others, B or T cells, the blood-central nervous system barrier, complement, polynuclear cells, AQP4-antibody linkage and AQP4 activity. The numerous agents under development are the result of a major collaborative effort all over the world. After the considerable progress on diagnosis, we are now close to class I evidence for a therapeutic effect of several drugs in NMO spectrum disorders, most notably with the anti-interleukin-6 receptor antibody (satralizumab) and anti-complement-5 antibody (eculizumab).
Editorial: Advances in Neuromyelitis Optica Spectrum Disorders

Yu Cai,Jodie M. Burton,Fu-Dong Shi,Wei Qiu,Yangtai Guan

DOI: https://doi.org/10.3389/fneur.2022.1005164

IF: 3.4

2022-01-01

Frontiers in Neurology

Abstract:COPYRIGHT © 2022 Cai, Burton, Shi, Qiu and Guan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Editorial: Advances in neuromyelitis optica spectrum disorders
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

Marios C Papadopoulos,Jeffrey L Bennett,Alan S Verkman

DOI: https://doi.org/10.1038/nrneurol.2014.141

Abstract:Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by inflammatory demyelinating lesions in the spinal cord and optic nerve, potentially leading to paralysis and blindness. NMO can usually be distinguished from multiple sclerosis (MS) on the basis of seropositivity for IgG antibodies against the astrocytic water channel aquaporin-4 (AQP4). Differentiation from MS is crucial, because some MS treatments can exacerbate NMO. NMO pathogenesis involves AQP4-IgG antibody binding to astrocytic AQP4, which causes complement-dependent cytotoxicity and secondary inflammation with granulocyte and macrophage infiltration, blood-brain barrier disruption and oligodendrocyte injury. Current NMO treatments include general immunosuppressive agents, B-cell depletion, and plasma exchange. Therapeutic strategies targeting complement proteins, the IL-6 receptor, neutrophils, eosinophils and CD19--all initially developed for other indications--are under clinical evaluation for repurposing for NMO. Therapies in the preclinical phase include AQP4-blocking antibodies and AQP4-IgG enzymatic inactivation. Additional, albeit currently theoretical, treatment options include reduction of AQP4 expression, disruption of AQP4 orthogonal arrays, enhancement of complement inhibitor expression, restoration of the blood-brain barrier, and induction of immune tolerance. Despite the many therapeutic options in NMO, no controlled clinical trials in patients with this condition have been conducted to date.
Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: from Bench to Bedside

Wenjiao Zhu,Yaling Zhang,Zhen Wang,Ying Fu,Yaping Yan

DOI: https://doi.org/10.1007/s12264-020-00525-3

2020-01-01

Abstract:Neuromyelitis optica (NMO)/NMO spectrum disorder (NMOSD) is a chronic, recurrent, antibody-mediated, inflammatory demyelinating disease of the central nervous system, characterized by optic neuritis and transverse myelitis. The binding of NMO-IgG with astrocytic aquaporin-4 (AQP4) functions directly in the pathogenesis of >60% of NMOSD patients, and causes astrocyte loss, secondary inflammatory infiltration, demyelination, and neuron death, potentially leading to paralysis and blindness. Current treatment options, including immunosuppressive agents, plasma exchange, and B-cell depletion, are based on small retrospective case series and open-label studies. It is noteworthy that monoclonal antibody (mAb) therapy is a better option for autoimmune diseases due to its high efficacy and tolerability. Although the pathophysiological mechanisms of NMOSD remain unknown, increasingly, therapeutic studies have focused on mAbs, which target B cell depletion, complement and inflammation cascade inactivation, blood-brain-barrier protection, and blockade of NMO-IgG-AQP4 binding. Here, we review the targets, characteristics, mechanisms of action, development, and potential efficacy of mAb trials in NMOSD, including preclinical and experimental investigations.
Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model

Yuanyuan Zhang,Kewei Tian,Hong Jiang,Beibei Wang,Shu Han

DOI: https://doi.org/10.1155/2018/4187347

2018-01-01

Mediators of Inflammation

Abstract:Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease that mainly affects the spinal cord and optic nerve, causing blindness and paralysis in some individuals. Moreover, NMO may cause secondary complement-dependent cytotoxicity (CDC), leading to oligodendrocyte and neuronal damage. In this study, a rodent NMO model, showing typical NMO pathogenesis, was induced with NMO-IgG from patient serum and human complement. We then tested whether the combination of C16, an αvβ3 integrin-binding peptide, and angiopoietin-1 (Ang1), a member of the endothelial growth factor family, could alleviate NMO in the model. Our results demonstrated that this combination therapy significantly decreased disease severity, inflammatory cell infiltration, secondary demyelination, and axonal loss, thus reducing neural death. In conclusion, our study suggests a possible treatment that can relieve progressive blindness and paralysis in an animal model of NMO through improvement of the inflammatory milieu.
Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model

Yi Xie,Bo Chen,Qiong Wang,Xuejiao Chen,Wenwen Lai,Yaping Xu,Saiyue Deng,Zhiyuan Yu,Minjie Xie,Bitao Bu,Dapeng Mou,Chenju Yi,Fengfei Ding,Wei Wang

DOI: https://doi.org/10.1002/ana.26650

IF: 11.2

2023-01-01

Annals of Neurology

Abstract:ObjectiveNeuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease that leads to severe disability. A large proportion of NMOSD patients are seropositive for aquaporin-4 autoantibodies (AQP4-IgG, named as NMO-IgG) targeting AQP4, which is selectively expressed on astrocytes in the central nervous system. This study tests the hypothesis that in response to NMO-IgG, the pathogenic astrocyte-derived exosomes are released and injure the neighboring cells.MethodsIgG purified from serum of either NMOSD patients or healthy controls was used to generate astrocyte-derived exosomes (AST-Exos(NMO) vs AST-Exos(CON)) in cultured rat astrocytes. The exosomes were respectively delivered to cultured rat oligodendrocytes in vitro, tissue culture of rat optic nerve ex vivo, and rat optic nerve in vivo to evaluate the pathogenic roles of AST-Exos(NMO). The microRNA (miRNA) sequencing of AST-Exos and verification were performed to identify the key pathogenic miRNA. The custom-designed adeno-associated virus (AAV) antagonizing the key miRNA was evaluated for its therapeutic effects in vivo. Moreover, the serum levels of the key exosomal miRNA were measured between NMOSD patients and healthy controls.ResultsAST-Exos(NMO) led to notable demyelination in both cultured oligodendrocytes and optic nerve tissue. Exosomal miR-129-2-3p was identified as the key miRNA mediating the demyelinating pathogenesis via downstream target gene SMAD3. AAV antagonizing miR-129-2-3p protected against demyelination in an NMOSD rodent model. The serum exosomal miR-129-2-3p level was significantly elevated in NMOSD patients and correlated with disease severity.InterpretationAstrocytes targeted by NMO-IgG release pathogenic exosomes that could potentially be used as therapeutic targets or disease monitoring biomarkers in NMOSD. ANN NEUROL 2023
Astroglial connexin 43 is a novel therapeutic target for chronic multiple sclerosis model

Ezgi Ozdemir Takase,Ryo Yamasaki,Satoshi Nagata,Mitsuru Watanabe,Katsuhisa Masaki,Hiroo Yamaguchi,Jun-ichi Kira,Hideyuki Takeuchi,Noriko Isobe

DOI: https://doi.org/10.1038/s41598-024-61508-2

IF: 4.6

2024-05-14

Scientific Reports

Abstract:In chronic stages of multiple sclerosis (MS) and its animal model, experimental autoimmune encephalitis (EAE), connexin (Cx)43 gap junction channel proteins are overexpressed because of astrogliosis. To elucidate the role of increased Cx43, the central nervous system (CNS)-permeable Cx blocker INI-0602 was therapeutically administered. C57BL6 mice with chronic EAE initiated by MOG 35-55 received INI-0602 (40 mg/kg) or saline intraperitoneally every other day from days post-immunization (dpi) 17–50. Primary astroglia were employed to observe calcein efflux responses. In INI-0602-treated mice, EAE clinical signs improved significantly in the chronic phase, with reduced demyelination and decreased CD3 + T cells, Iba-1 + and F4/80 + microglia/macrophages, and C3 + GFAP + reactive astroglia infiltration in spinal cord lesions. Flow cytometry analysis of CD4 + T cells from CNS tissues revealed significantly reduced Th17 and Th17/Th1 cells (dpi 24) and Th1 cells (dpi 50). Multiplex array of cerebrospinal fluid showed significantly suppressed IL-6 and significantly increased IL-10 on dpi 24 in INI-0602-treated mice, and significantly suppressed IFN-γ and MCP-1 on dpi 50 in the same group. In vitro INI-0602 treatment inhibited ATP-induced calcium propagations of Cx43 +/+ astroglial cells to similar levels of those of Cx43 −/− cells. Astroglial Cx43 hemichannels represent a novel therapeutic target for chronic EAE and MS.

multidisciplinary sciences
Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review

Agni M. Konitsioti,Harald Prüss,Sarah Laurent,Gereon R. Fink,Christoph Heesen,Clemens Warnke

DOI: https://doi.org/10.1007/s00415-024-12642-4

2024-09-16

Journal of Neurology

Abstract:Importance B-cell-targeting monoclonal antibodies have demonstrated safety and efficacy in multiple sclerosis or anti-aquaporin-4 IgG positive neuromyelitis optica spectrum disorder. However, these therapies do not facilitate drug-free remission, which may become possible with cell-based therapies, including chimeric antigen receptor (CAR) T cells. CAR T-cell therapy holds promise for addressing other antibody-mediated CNS disorders, e.g., MOG-associated disease or autoimmune encephalitis. Objective To provide an overview of the current clinical knowledge on CAR T-cell therapy in central nervous system autoimmunity. Evidence review We searched PubMed, Embase, Google Scholar, PsycINFO, and clinicaltrials.gov using the terms 'CAR T cell' and 'multiple sclerosis/MS' or 'neuromyelitis optica/spectrum diseases/NMOSD' or 'MOG-associated disease/MOGAD 'or' autoimmune encephalitis' or 'neuroimmunology'. Findings An ongoing phase I clinical trial has indicated the safety and benefits of anti-BCMA CAR T cells in 12 patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder. Case reports involving two individuals with progressive multiple sclerosis and one patient with stiff-person syndrome demonstrated a manageable safety profile following treatment with anti-CD19 CAR T cells. Recruitment has commenced for two larger studies in MS, and a phase I open-label basket study is underway to evaluate BCMA-directed CAR T cells in various antibody-associated inflammatory diseases, including MOG-associated disease. Preclinical research on NMDA receptor antibody autoimmune encephalitis treated with chimeric autoantibody receptor T cells generated promising data. Conclusions and relevance There is minimal evidence of the benefits of CAR T-cell therapy in individuals with central nervous system-directed autoimmunity. Nevertheless, multicenter controlled clinical trials with a manageable safety profile appear feasible and are warranted due to very promising case experiences.

clinical neurology
Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder.

Yuge Wang,Yifan Zhou,Xiaobo Sun,Tingting Lu,Lei Wei,Ling Fang,Chen Chen,Qiao Huang,Xueqiang Hu,Zhengqi Lu,Lisheng Peng,Wei Qiu

DOI: https://doi.org/10.1159/000464135

2016-01-01

NeuroImmunoModulation

Abstract:Objective: To screen cytokines and chemokines and determine their dynamic changes in the serum and cerebrospinal fluid (CSF) of patients with neuromyelitis optica spectrum disorder (NMOSD). Methods: Eight NMOSD with seropositive aquaporin-4 antibody (AQP4-IgG) were enrolled, as well as 8 matched patients with multiple sclerosis (MS) and 8 with noninflammatory neurological diseases, who were included as controls. In total, 102 cytokines and 34 chemokines were detected in the CSF and serum of NMOSD patients and controls. Results: CSF interleukin (IL)-17A levels were significantly higher in NMOSD patients in the relapsing phase (27.15 +/- 11.33) than in those in the remitting phase (10.04 +/- 3.11, p = 0.0017), and patients with MS (14.72 +/- 3.20, p = 0.0283) and other controls (10.39 +/- 11.38, p = 0.0021). CSF IL-6 levels were higher in the NMOSD patients in the relapsing phase (12.23 +/- 3.47) than in those in the remitting phase (5.87 +/- 2.78, p = 0.0001), and MS patients (7.38 +/- 2.35, p = 0.0033) and other controls (7.50 +/- 0.37, p = 0.0043). CSF CCL19 levels were also significantly higher in NMOSD patients in the relapsing phase (35.87 +/- 27.07) than in those in the remitting phase (10.71 +/- 3.62, p = 0.0215). Serum IL-19 levels were lower in NMOSD patients in the relapsing phase (6.23 +/- 1.95) than in those in the remitting phase (10.72 +/- 4.46, p = 0.0092). Further, there was a positive, significant correlation between serum IL-9 concentration and the Expanded Disability Status Scale score in the NMOSD patients in the relapsing phase (p = 0.04). Conclusion: In addition to IL-6 and IL-17A, IL-16 and CCL19 act as proinflammatory cytokines/chemokines, while IL-19 plays a protective role in NMOSD pathogenesis. (C) 2017 S.Karger AG, Basel
The Emerging Role of Microglia in Neuromyelitis Optica

Tingjun Chen,Dale B. Bosco,Yanlu Ying,Dai-Shi Tian,Long-Jun Wu

DOI: https://doi.org/10.3389/fimmu.2021.616301

IF: 7.3

2021-02-19

Frontiers in Immunology

Abstract:Neuromyelitis optica (NMO) is an autoantibody-triggered neuro-inflammatory disease which preferentially attacks the spinal cord and optic nerve. Its defining autoantibody is specific for the water channel protein, aquaporin‐4 (AQP4), which primarily is localized at the end-feet of astrocytes. Histopathology studies of early NMO lesions demonstrated prominent activation of microglia, the resident immune sentinels of the central nervous system (CNS). Significant microglial reactivity is also observed in NMO animal models induced by introducing AQP4-IgG into the CNS. Here we review the potential roles for microglial activation in human NMO patients as well as different animal models of NMO. We will focus primarily on the molecular mechanisms underlying microglial function and microglia-astrocyte interaction in NMO pathogenesis. Understanding the role of microglia in NMO pathology may yield novel therapeutic approaches for this disease.

immunology
The Role of Chimeric Antigen Receptor T‐Cell Therapy in Immune‐Mediated Neurological Diseases

Gavin Brittain,Elisa Roldan,Tobias Alexander,Riccardo Saccardi,John A. Snowden,Basil Sharrack,Raffaella Greco

DOI: https://doi.org/10.1002/ana.27029

IF: 11.2

2024-07-19

Annals of Neurology

Abstract:Despite the use of 'high efficacy' disease‐modifying therapies, disease activity and clinical progression of different immune‐mediated neurological diseases continue for some patients, resulting in accumulating disability, deteriorating social and mental health, and high economic cost to patients and society. Although autologous hematopoietic stem cell transplant is an effective treatment modality, it is an intensive chemotherapy‐based therapy with a range of short‐ and long‐term side‐effects. Chimeric antigen receptor T‐cell therapy (CAR‐T) has revolutionized the treatment of B‐cell and other hematological malignancies, conferring long‐term remission for otherwise refractory diseases. However, the toxicity of this treatment, particularly cytokine release syndrome and immune effector cell‐associated neurotoxicity syndrome, and the complexity of production necessitate the need for a high level of specialization at treating centers. Early‐phase trials of CAR‐T therapies in immune‐mediated B cell driven conditions, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder and myasthenia gravis, have shown dramatic clinical response with few adverse events. Based on the common physiopathology, CAR‐T therapy in other immune‐mediated neurological disease, including multiple sclerosis, chronic inflammatory polyradiculopathy, autoimmune encephalitis, and stiff person syndrome, might be an effective option for patients, avoiding the need for long‐term immunosuppressant medications. It may prove to be a more selective immunoablative approach than autologous hematopoietic stem cell transplant, with potentially increased efficacy and lower adverse events. In this review, we present the state of the art and future directions of the use of CAR‐T in such conditions. ANN NEUROL 2024

neurosciences,clinical neurology
Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

Mingchao Shi,Fengna Chu,Tao Jin,Jie Zhu

DOI: https://doi.org/10.1111/cns.13836

2022-04-15

Abstract:Several drugs with different mechanisms and targets have been applied in clinic for therapy of NMOSD patients, included first‐line, second‐line, and new biologicals therapies. Other novel insights into therapeutic possibilities in NMOSD include targeting Th17 cells and blocking IL23/IL17/Th17 pathway and stem cell therapies, etc.Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system (CNS), which is a severely disabling disorder leading to devastating sequelae or even death. Repeated acute attacks and the presence of aquaporin‐4 immunoglobulin G (AQP4‐IgG) antibody are the typical characteristics of NMOSD. Recently, the phase III trials of the newly developed biologicals therapies have shown their effectiveness and good tolerance to a certain extent when compared with the traditional therapy with the first‐ and second‐line drugs. However, there is still a lack of large sample, double‐blind, randomized, clinical studies to confirm their efficacy, safety, and tolerability. Especially, these drugs have no clear effect on NMOSD patients without AQP4‐IgG and refractory patients. Therefore, it is of strong demand to further conduct large sample, double‐blind, randomized, clinical trials, and novel therapeutic possibilities in NMOSD are discussed briefly here.

pharmacology & pharmacy,neurosciences
A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

Heather Y F Yong,Jodie M Burton

DOI: https://doi.org/10.1007/s11910-023-01287-x

Abstract:Purpose of review: Neuromyelitis optica spectrum disorder (NMOSD) is a rare but highly disabling disease of the central nervous system. Unlike multiple sclerosis, disability in NMOSD occurs secondary to relapses that, not uncommonly, lead to blindness, paralysis, and death. Recently, newer, targeted immunotherapies have been trialed and are now in the treatment arsenal. We have endeavoured to evaluate the current state of NMOSD therapeutics. Recent findings: This review provides a pragmatic evaluation of recent clinical trials and post-marketing data for rituximab, inebilizumab, satralizumab, eculizumab, and ravalizumab, contrasted to older agents. We also review contemporary issues such as treatment in the context of SARS-CoV2 infection and pregnancy. There has been a dramatic shift in NMOSD morbidity and mortality with earlier and improved disease recognition, diagnostic accuracy, and the advent of more effective, targeted therapies. Choosing a maintenance therapy remains nuanced depending on patient factors and accessibility. With over 100 putative agents in trials, disease-free survival is now a realistic goal for NMOSD patients.
Inhibition of complement C3 signaling ameliorates locomotor and visual dysfunction in autoimmune inflammatory diseases

Li Xu,Huiming Xu,Siqi Chen,Wei Jiang,Shabbir Khan Afridi,Yuge Wang,Xin Ren,Yipeng Zhao,Shuiqing Lai,Xiusheng Qiu,Yu-Wen Alvin Huang,Yaxiong Cui,Hui Yang,Wei Qiu,Changyong Tang

DOI: https://doi.org/10.1016/j.ymthe.2023.07.017

IF: 12.91

2023-07-01

Molecular Therapy

Abstract:Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system (CNS) characterized by transverse myelitis and optic neuritis. The pathogenic serum IgG antibody against the aquaporin-4 (AQP4) on astrocytes triggers the activation of the complement cascade, causing astrocyte injury, followed by oligodendrocyte injury, demyelination, and neuronal loss. Complement C3 is positioned as a central player that relays upstream initiation signals to activate downstream effectors, potentially stimulating and amplifying host immune and inflammatory responses. However, whether targeting the inhibition of C3 signaling could ameliorate tissue injury, locomotor defects, and visual impairments in NMO remains to be investigated. In this study, using the targeted C3 inhibitor CR2-Crry led to a significant decrease in complement deposition and demyelination in both slice cultures and focal intracerebral injection models. Moreover, the treatment downregulated the expression of inflammatory cytokines and improved motor dysfunction in a systemic NMO mouse model. Similarly, employing serotype 2/9 adeno-associated virus (AAV2/9) to induce permanent expression of CR2-Crry resulted in a reduction in visual dysfunction by attenuating NMO-like lesions. Our findings reveal the therapeutic value of inhibiting the complement C3 signaling pathway in NMO.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model

Shihe Jiang,Xindi Li,Yan Li,Zhilin Chang,Meng Yuan,Ying Zhang,Huimin Zhu,Yuwen Xiu,Hengri Cong,Linlin Yin,Zhen-Wei Yu,Junwan Fan,Wenyan He,Kaibin Shi,De-Cai Tian,Jing Zhang,Alexei Verkhratsky,Wei-Na Jin,Fu-Dong Shi

DOI: https://doi.org/10.1126/scitranslmed.adg5116

2024-02-28

Abstract:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy of the central nervous system, mediated by antibodies against aquaporin-4 water channel protein (AQP4-Abs), resulting in damage of astrocytes with subsequent demyelination and axonal damage. Extracellular communication through astrocyte-derived extracellular vesicles (ADEVs) has received growing interest in association with astrocytopathies. However, to what extent ADEVs contribute to NMOSD pathogenesis remains unclear. Here, through proteomic screening of patient-derived ADEVs, we observed an increase in apolipoprotein E (APOE)-rich ADEVs in patients with AQP4-Abs-positive NMOSD. Intracerebral injection of the APOE-mimetic peptide APOE130-149 attenuated microglial reactivity, neuroinflammation, and brain lesions in a mouse model of NMOSD. The protective effect of APOE in NMOSD pathogenesis was further established by the exacerbated lesion volume in APOE-deficient mice, which could be rescued by exogenous APOE administration. Genetic knockdown of the APOE receptor lipoprotein receptor-related protein 1 (LRP1) could block the restorative effects of APOE130-149 administration. The transfusion ADEVs derived from patients with NMOSD and healthy controls also alleviated astrocyte loss, reactive microgliosis, and demyelination in NMOSD mice. The slightly larger beneficial effect of patient-derived ADEVs as compared to ADEVs from healthy controls was further augmented in APOE-/- mice. These results indicate that APOE from astrocyte-derived extracellular vesicles could mediate disease-modifying astrocyte-microglia cross-talk in NMOSD.
Astrocyteâ€�derived exosomes contribute to pathologies of NMOSD in rodent model

Yi Xie,Bo Chen,Qiong Wang,Xuejiao Chen,Wenwen Lai,Yaping Xu,Saiyue Deng,Zhiyuan Yu,Minjie Xie,Bitao Bu,Dapeng Mou,Chenju Yi,Fengfei Ding,Wei Wang

DOI: https://doi.org/10.1002/ana.26650

IF: 11.2

2023-03-28

Annals of Neurology

Abstract:Objective Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease that leads to severe disability. A large proportion of NMOSD patients are seropositive for aquaporinâ€�4 autoantibodies (AQP4â€�IgG, named as NMOâ€�IgG) targeting the AQP4, which is selectively expressed on astrocytes in central nervous system (CNS). This study tests the hypothesis that in response to NMOâ€�IgG, the pathogenic astrocyteâ€�derived exosomes are released and injure the neighboring cells. Methods IgG purified from serum of either NMOSD patients or healthy controls were used to generate astrocyteâ€�derived exosomes (ASTâ€�ExosNMO versus ASTâ€�ExosCON) in cultured rat astrocytes. The exosomes were respectively delivered to cultured rat oligodendrocytes in vitro, tissue culture of rat optic nerve ex vivo, and rat optic nerve in vivo to evaluate the pathogenic roles of ASTâ€�ExosNMO. The miRNA sequencing of ASTâ€�Exos and verification were performed to identify the key pathogenic miRNA. The customâ€�designed AAV antagonizing the key miRNA was evaluated for its therapeutic effects in vivo. Moreover, the serum levels of the key exosomal miRNA were measured between NMOSD patients and healthy controls. Results ASTâ€�ExosNMO led to notable demyelination both in cultured oligodendrocytes and optic nerve tissue. Exosomal miRâ€�129â€�2â€�3p was identified as the key miRNA mediating the demyelinating pathogenesis via downstream target gene SMAD3. AAV antagonizing miRâ€�129â€�2â€�3p protected against demyelination in NMOSD rodent model. The serum exosomal miRâ€�129â€�2â€�3p level was significantly elevated in NMOSD patients and correlated with disease severity. Interpretation Astrocytes targeted by NMOâ€�IgG release pathogenic exosomes that could potentially be used as therapeutic targets, or disease monitoring biomarkers in NMOSD. This article is protected by copyright. All rights reserved.

neurosciences,clinical neurology
Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials

Tao Xue,Jiahao Yu,Shujun Chen,Zilan Wang,Yanbo Yang,Zhouqing Chen,Zhong Wang

DOI: https://doi.org/10.3389/fneur.2020.604445

IF: 3.4

2020-12-17

Frontiers in Neurology

Abstract:Background: Neuromyelitis optica spectrum disorder (NMOSD), an autoimmune inflammatory disorder of the central nervous system, often leads to vision loss or paralysis. This meta-analysis focused on the assessment of the monoclonal antibody therapy in NMOSD and compared different targets of monoclonal antibodies with each other in terms of efficacy and safety outcomes. Method: We searched through the databases of MEDLINE, EMBASE, Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov for randomized controlled trials (RCTs) evaluating monoclonal antibody therapy in NMOSD up to April 2020. Results: We identified seven randomized controlled trials (RCTs), including 775 patients (monoclonal antibody group, n = 485 and placebo group, n = 290). Monoclonal antibody therapy decreased relapse risk (RR 0.33, 95% CI 0.21–0.52, P < 0.00001), annualized relapse rate (ARR) (mean −0.28, 95% CI −0.35−0.20, P < 0.00001), expanded disability status scale score (EDSS) (mean −0.19, 95% CI −0.32−0.07, P = 0.002) and serious adverse events (RR 0.78, 95% CI 0.61–1.00, P = 0.05). However, we did not observe any significant difference in terms of adverse events or mortality. Further, the subgroup analysis demonstrated that the anti-complement protein C5 monoclonal antibody (eculizumab) might have a lower relapse risk (RR 0.07, 95% CI 0.02–0.23, P < 0.0001) in the AQP4 seropositive patients, and anti-interleukin-6 receptor monoclonal antibodies (satralizumab and tocilizumab) showed decreased EDSS score (mean −0.17, 95% CI −0.31−0.02, P = 0.02) more effectively than other monoclonal antibodies. Conclusions: Monoclonal antibodies were effective and safe in NMOSD. Different targets of monoclonal antibodies might have their own advantages.

neurosciences,clinical neurology

Commentary: Targeting Chemoattractant Chemokine (C–C Motif) Ligand 2 Derived from Astrocytes is a Promising Therapeutic Approach in the Treatment of Neuromyelitis Optica Spectrum Disorders

Targeting chemoattractant chemokine (C–C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders

Astrocyte-Microglia Interaction Drives Evolving Neuromyelitis Optica Lesion

Editorial: Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Editorial: Advances in Neuromyelitis Optica Spectrum Disorders

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: from Bench to Bedside

Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model

Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model

Astroglial connexin 43 is a novel therapeutic target for chronic multiple sclerosis model

Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review

Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder.

The Emerging Role of Microglia in Neuromyelitis Optica

The Role of Chimeric Antigen Receptor T‐Cell Therapy in Immune‐Mediated Neurological Diseases

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

Inhibition of complement C3 signaling ameliorates locomotor and visual dysfunction in autoimmune inflammatory diseases

APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model

Astrocyteâ€�derived exosomes contribute to pathologies of NMOSD in rodent model

Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials